The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection

Study Overview
=================
Brief Summary
-----------------
Traditional Chinese medicine is regarded as a dietary supplement in many countries around the world. Dietary supplement, NRICM101, has been available for people who diagnosed, suspected or prevented for coronavirus disease 2019 (COVID-19) in September 2020. It is expected to help people not to progress to severe illness, and reduce lung damage and mortality. The investigators gather the effects of people who taking NRICM101 using the Real-World Big Data Study and the network feedback information collection model. This study can be used as a reference for global prevention and control of coronavirus disease 2019 (COVID-19).

Detailed Description
-----------------
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is raging around the world. Because of its strong spread, variability, survivability, and invisibility, the number of infected people rise rapidly. On March 11, 2020, the WHO officially declared COVID-19 as a pandemic disease. As of October 3, 2020, the number of confirmed cases has exceeded 34 million, and the cumulative deaths have exceeded 1 million. There are still no drugs to treatment the coronavirus disease 2019 (COVID-19). Due to the mutation of virus rapidly, vaccine development cannot be completed in a short period of time. At the beginning of the infection outbreak, the governments of China and South Korea, adopted a cooperative of Chinese and Western medicine to treatment the coronavirus disease 2019 (COVID-19). In addition to the reported good clinical effects, Chinese medicine prescriptions have included in diagnosis and treatment guideline of these two countries. Traditional Chinese medicine is regarded as a dietary supplement in many countries around the world. Dietary supplement, NRICM101, has been available for people who diagnosed, suspected or prevented for coronavirus disease 2019 (COVID-19) in September 2020. It is expected to help people not to progress to severe illness, and reduce lung damage and mortality. The investigators gather the effects of people who taking NRICM101 using the Real-World Big Data Study and the network feedback information collection model. This study can be used as a reference for global prevention and control of coronavirus disease 2019 (COVID-19).

Official Title
-----------------
The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection

Conditions
-----------------
SARS-CoV-2, Covid 19

Intervention / Treatment
-----------------
* Dietary Supplement: NRICM101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who confirmed, suspected or prevented infected of COVID 19 disease and take dietary supplement NRICM101 Exclusion Criteria: Those who refuse to participate in observational research.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NRICM101<br>Subjects who confirmed, suspected or prevented infected of COVID 19 disease and received dietary supplement NRICM101 | Dietary Supplement: NRICM101<br>* Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals Indication: Externally contracted seasonal epidemic Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| negative of COVID-19 test | receive COVID 19 test and the result is negative | 1 day to 2 months | 
| free of COVID 19 disease symptoms and signs | free of COVID 19 disease symptoms and signs after took NRICM101 | 1 day to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NRICM101, Covid 19, SARS-CoV-2